Correction to: Advances in the development paradigm of biosample‐based biosensors for early ultrasensitive detection of alzheimer’s disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1477-3155
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: Advances in the development paradigm of biosample‐based biosensors for early ultrasensitive detection of alzheimer’s disease ; volume:19 ; number:1 ; day:26 ; month:4 ; year:2021 ; pages:1 ; date:12.2021
Journal of nanobiotechnology ; 19, Heft 1 (26.4.2021), 1, 12.2021
- Urheber
-
Karki, Hem Prakash
Jang, Yeongseok
Jung, Jinmu
Oh, Jonghyun
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12951-021-00850-3
- URN
-
urn:nbn:de:101:1-2021090420492826323252
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Karki, Hem Prakash
- Jang, Yeongseok
- Jung, Jinmu
- Oh, Jonghyun
- SpringerLink (Online service)
Ähnliche Objekte (12)
Advances in the development paradigm of biosample‐based biosensors for early ultrasensitive detection of alzheimer’s disease
Advances in Alzheimer’s Disease Drug Development
Ultrasensitive tau biosensor cells detect no seeding in Alzheimer’s disease CSF
Advances in Drug Therapy for Alzheimer’s Disease
Advances in developing novel therapeutic strategies for Alzheimer’s disease
Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances
Advances in the development of new biomarkers for Alzheimer’s disease
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease
Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays
Advances in Modeling Alzheimer's Disease In Vitro
An in vitro paradigm to assess potential anti-Aβ antibodies for Alzheimer’s disease
Development of an ultra-sensitive assay for early diagnosis of Alzheimer's disease
Advances in the development paradigm of biosample‐based biosensors for early ultrasensitive detection of alzheimer’s disease
Advances in Alzheimer’s Disease Drug Development
Ultrasensitive tau biosensor cells detect no seeding in Alzheimer’s disease CSF
Advances in Drug Therapy for Alzheimer’s Disease
Advances in developing novel therapeutic strategies for Alzheimer’s disease
Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances
Advances in the development of new biomarkers for Alzheimer’s disease
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease
Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays
Advances in Modeling Alzheimer's Disease In Vitro
An in vitro paradigm to assess potential anti-Aβ antibodies for Alzheimer’s disease
Development of an ultra-sensitive assay for early diagnosis of Alzheimer's disease
Advances in the development paradigm of biosample‐based biosensors for early ultrasensitive detection of alzheimer’s disease
Advances in Alzheimer’s Disease Drug Development
Ultrasensitive tau biosensor cells detect no seeding in Alzheimer’s disease CSF
Advances in Drug Therapy for Alzheimer’s Disease
Advances in developing novel therapeutic strategies for Alzheimer’s disease
Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances
Advances in the development of new biomarkers for Alzheimer’s disease
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease
Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays
Advances in Modeling Alzheimer's Disease In Vitro
An in vitro paradigm to assess potential anti-Aβ antibodies for Alzheimer’s disease